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Nitrous oxide (N 20) is an anesthetic gas known to produce an analgesic effect at subanesthetic concentrations. This 
analgesic property of N20 can be clinically exploited in a broad range of conditions where pain relief is indicated. 
The mechanism of this analgesic effect was long thought to be nonspecific in nature, but a landmark study by 
Berkowitz and others in 1976 first implicated an opioid mechanism of action, possibly via N20-stimulated neuronal 
release of endogenous opioid peptides to activate opioid receptors. N20-induced release of opioid peptide has 
been demonstrated in both in vivo and in vitro preparations. Reversal of N20 -i nduced antinociception in animals by 
narcotic antagonists has been reported by a number of laboratories. Subsequent studies have utilized more selec-
tive opioid antagonists to identify the opioid receptor subtypes involved in the antinociceptive effect of N20. Exten-
sive pharmacological testing in the mouse abdominal constriction and rat hot plate paradigms have established that 
N20-induced antinociception is mediated by K-opioid receptors in the former and byµ,- and f-opioid receptors in the 
latter. Current studies focus on two recent developments. The poor responsiveness of the DBA/2J mouse strain to 
N20 has led to pharmacogenetic studies that hope to identify the underlying genetic basis for antinociceptive 
responsiveness to N20 . Other research suggests an involvement of nitric oxide (NO) in mediating the antinociceptive 
effects of N20 in both rats and mice. 
Nitrous oxide Opioid peptides Antinociception 
Introduction 
N2O is one of the simpler inorganic chemicals that is 
utilized clinically. First identified by Joseph Priestley 
some 200 years ago, N20 possesses three outstanding 
clinical properties. First, it produces analgesia. The anal-
gesic effect caused by inhalation of 20% N2O in oxygen 
is reportedly equivalent to that evoked by 15 mg mor-
phine sulfate (9). N2O-induced analgesia has been uti-
lized to relieve pain associated with childbirth (40), myo-
cardial infarction (36, 73), diagnostic or interventional 
procedures (6,29,35), postsurgical recovery (23,50,51), 
intractable pain (38), refractory pain (16), and accident 
and trauma (2, 12, 72). Second, N2O produces an anesthe-
tic effect. N2O enjoys a prominent role in medical history 
because it was the first drug used for surgical anesthesia. 
Despite its low anesthetic potency, it continues to be 
widely used in anesthesiology because of its ability to re-
duce the minimum alveolar concentration of other inha-
lation agents. Third, N2O produces a significant anxio-
lytic effect. In clinical dentistry, it is popularly used for 
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producing conscious sedation, a state in which patients 
experience reduced anxiety and pain (67). Recent re-
search indicates that this antianxiety effect is distinct 
from the analgesic action of NP and may be mediated 
by central benzodiazepine mechanisms (13 ,57,64). 
The Opioid Nature of N20-Induced Antinociception 
The ability of inhaled N2O to suppress pain was first 
reported in 1800 by Sir Humphry Davy, who suggested 
that it might be used to relieve pain during surgical oper-
ations (68). Surgical anesthesia was first demonstrated 
by Horace Wells in 1844, who had one of his own teeth 
extracted painlessly while he was under N2O. Though 
N2O was used for dental extractions and other surgical 
procedures for many years, its mechanism of action was 
ascribed to be a nebulous "nonspecific" action on the 
brain, most probably the result of a generalized depres-
sion of central nervous system function (69). 
Most studies of N2O-induced antinociception in mice 
have been carried out using the abdominal constriction 
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test. In this procedure, mice receive an intraperitoneal 
(i.p.) injection of a dilute concentration of a chemical ir-
ritant such as phenylquinone or glacial acetic acid. Ex-
actly 5 min later, the number of abdominal constrictions 
(i.e., lengthwise stretches of the torso with concave arch-
ing of the back) are counted for a fixed period. Exposure 
to increasing concentrations of N2O causes a dose-
related suppression in the number of abdominal con-
strictions induced by i.p. injection of phenylquinone or 
dilute acetic acid (5 ,58). The first evidence suggesting a 
specific mechanism of action was provided by Berkowitz 
and coworkers, who reported that the antinociceptive ef-
fect ofN2O in mice was significantly reduced by subcuta-
neous (s.c.) pretreatment with 5.0 mg/kg naloxone or 
naltrexone (4,5) . Quock and associates have conducted 
more extensive dose-response studies, in which increas-
ing s.c. pretreatment doses (1.0-10 mg/kg) of naloxone 
caused a progressive shift to the right of the dose-
response curve for N2O-induced antinociception (56). 
Pretreatment with 10 mg/kg ( + )-naloxone, s.c. , was 
completely ineffective in influencing N2O-induced anti-
nociception, demonstrating that the ability of naloxone 
to attenuate N2O was a stereospecific drug effect at the 
opioid receptor and not the consequence of some non-
specific action of naloxone (58). 
Systemic pretreatment with 10 mg/kg naltrexone 
methylbromide was also ineffective in altering N20-
induced antinociception (58). However, following in-
tracerebroventricular (i.e. v .) pretreatment with this 
quaternary ammonium form of naltrexone, there was an 
attenuation in N2O-induced antinociception. Because 
naltrexone methyl bromide does not penetrate the blood-
brain barrier, these findings implicate opioid receptors 
in the central nervous system as being responsible for 
mediating N2O-induced antinociception. Spinal cord 
opioid receptors are also involved in N2O-induced anti-
nociception because intrathecal (i.t.) pretreatment with 
0.5-5.0 µg naloxone causes a dose-dependent reduction 
in N2O-induced antinociception (55). 
Although most N2O studies in mice have been con-
ducted in the abdominal constriction test, some investi-
gations have utilized the hot plate paradigm. In this test, 
N2O-induced antinociception was antagonized by pre-
treatment with 20 mg/kg naloxone s.c. (66) but not by 
doses of ( + )-naloxone as high as 40 mg/kg (45). 
N2O-induced antinociception and antagonism of that 
antinociceptive effect have been most prominently dem-
onstrated in rats using the hot plate paradigm, tail with-
drawal from warm water, and the radiant heat tail flick 
test. In these models, antinociception is indicated by a 
significant prolongation in the latency time to reaction 
(hindpaw lick or escape attempt, tail withdrawal, and 
tail flick, respectively) to the thermal noxious stimulus. 
A general characteristic of N2O-induced antinociception 
in rats was the steep dose dependency of the drug effect. 
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The most consistent antinociceptive effect was in re-
sponse to 70-75% N2O, whereas 50% N2O evoked a 
highly variable response and lower concentrations were 
generally ineffective (32,48,81). 
The antinociceptive effect of N2O in rats is also sensi-
tive to antagonism by naloxone and naltrexone. As in 
mice, the antagonism of N2O in the rat tail flick test re-
quired higher systemic doses (5-10 mg/kg) than required 
for antagonism of morphine (4,81). In rats implanted 
with central microinjection cannulae, the antinocicep-
tive effect of 70% N2O in the hot plate test was signifi-
cantly antagonized by i.c.v. doses of 5.0 and 10 µg of 
naltrexone; increasing the i.e. v. dose of naltrexone to 20 
µg failed to increase the antagonism (32). When 20 ng 
naloxone was administered into the cisternum, the anti-
nociceptive effect of N2O in the tail flick test was imme-
diately terminated (48). 
Tolerance and cross-tolerance studies conducted in 
the mouse abdominal constriction and rat tail flick para-
digms suggest that N2O might act indirectly on opioid re-
ceptors via stimulated release of opioid peptides. Chron-
ic injections of up to 400 mg/kg morphine daily or s.c. 
implantation of 75-mg morphine pellets rendered ani-
mals tolerant to morphine-induced antinociception and 
also cross-tolerant to N2O-induced antinociception. How-
ever, after exposure to 75% N2O for 16-18 h, animals 
became tolerant to the antinociceptive effect of 80% 
N2O but they were not cross-tolerant to morphine-
induced antinociception (3,4) . Therefore, N2O tolerance 
induced by chronic exposure to N2O resulted mainly 
from depletion of the releasable pool of endogenous opi-
oid peptides with no concomitant change in responsive-
ness of opioid receptors to morphine. Consequently, in 
N2O-tolerant animals, morphine continued to produce 
antinociception. On the other hand, morphine tolerance 
reduced responsiveness to the antinociceptive effects of 
both morphine and opioid peptides released by N2O. 
N2O-induced release of opioid peptides has been dem-
onstrated in both in vivo and in vitro preparations. Ex-
posure to 75% N2O increased the amount of immunore-
active (IR) methionine-enkephalin (ME) in fractions of 
artificial cerebrospinal fluid (CSF) collected from ure-
thane-anesthetized, ventricular-cisternal perfused rats 
(59). Based on kinetic modeling, the rate of neuronal re-
lease of ME in this in vivo system was increased by 140% 
in the presence of 75% N2O (71). Comparable findings 
were reported in chronically cannulated dogs exposed to 
66-75% N2O (15), where there were significantly ele-
vated levels of IR ME and [Arg6-Phe7]ME in CSF sam-
ples collected from the third ventricle. In in vitro studies, 
exposure to increasing concentrations of N2O was shown 
to increase quantities of IR /3-endorphin (/3-EP) released 
from superfused rat basal hypothalamic cells (82). 
Results from pharmacological studies also support the 
hypothesis of an indirect action of N2O on opioid recep-
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tors. N2O-induced antinociception in rats was attenuat-
ed in a dose-related manner by i.e. v. pretreatment with 
50-200 µ,g of rabbit antiserum selective for {3-EP. In 
addition, i.e. v. pretreatment with the endopeptidase 
24.11-inhibitor phosphoramidon significantly potenti-
ated N2O-induced antinociception in rats (21) . Paradoxi-
cally, N2O-induced antinociception was not blocked by 
a ME antibody in i.c.v . doses as high as 400 µ,g (26). 
An alternative explanation is that N2O acts directly on 
the opioid receptor (22) . This hypothesis is based largely 
on in vitro radioligand binding studies, in which N2O, 
bubbling through tissue homogenate, reduced [3H]dihy-
dromorphine ([3H]DHM) binding in whole mouse brain 
(1) and resulted in appearance of an additional super-
high-affinity binding site for. [3H]naloxone in rat fore-
brain (10). In a more recent study of brain µ, -opioid and 
K-opioid receptors, 100% N2O or 2% halothane in oxy-
gen was bubbled through tissue homogenate prepared 
from whole guinea pig brain (49). N2O decreased the 
[3H]DHM binding affinity without affecting the density 
of binding sites and decreased the density of [3H]ethyl-
ketocyclazocine ([3H]EKC) binding sites without af-
fecting binding affinity. By comparison, halothane de-
creased both [3H]DHM and [3H]EKC binding affinities 
and reduced the density of binding sites for [3H]EKC. 
These results, suggest the authors, indicate the existence 
of specific membrane targets for anesthetic drugs. 
The Role of Multiple Opioid Receptor Subtypes 
in N20-Induced Antinociception 
The observation that N2O-induced antinociception 
was sensitive to antagonism by opioid receptor blockers 
was the initial indicator and strongest evidence for medi-
ation by endogenous opioid mechanisms. However, the 
s.c. doses of both naloxone and naltrexone required 
for antagonism of N2O-induced antinociception were 
greater than those needed to antagonize morphine. Also, 
the antagonism was always partial, never complete. 
There are two possible explanations for this incomplete 
antagonism of N2O antinociception by opioid receptor 
blockers. One, N2O-induced antinociception might be 
only partly determined by opioid mechanisms and may 
involve a nonopioid component. Two, N2O-induced 
antinociception might be mediated by opioid receptors 
other than the classical µ,-opioid receptor. It is now ac-
knowledged that naloxone and naltrexone can block µ, -
opioid receptors at low doses, but the dose of each must 
be increased in order to occupy non-µ,-opioid receptor 
types (53). The introduction of newer, subtype-selective 
antagonists has made it possible to more precisely iden-
tify the central opioid receptors that mediate N2O-
induced antinociception. 
One difficulty in determining the opioid receptors that 
mediate N2O-induced antinociception is that identifica-
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tion of opioid receptor subtypes depend on the type and 
intensity of noxious stimulus applied. It was previously 
suggested that different opioid receptor subtypes partici-
pate in supraspinal and spinal antinociceptive responses 
depending upon whether the test utilized chemical or 
thermal stimuli to evoke pain (78). For instance, anti-
nociception in the rat abdominal constriction test (chem-
ical stimulus) is mediated byµ,- and K-opioid, but not o-
opioid, receptors (65), whereas spinal antinociception in 
the hot plate test (thermal stimulus) is mediated byµ, and 
o, but not K, receptors (65). More current research has 
demonstrated that K-opioid receptor-mediated antinoci-
ception is intensity dependent in thermal nociceptive 
tests (43,52). On the other hand, studies to date show 
that even "selective" o-opioid agonists possess a residual 
cross-reactivity at µ,-opioid receptors (11), possibly pro-
viding an explanation to those reports of an antinocicep-
tive effect of o-opioid agonists in tests utilizing chemical 
noxious stimuli (54). Interpretation is further compli-
cated by findings of modulatory interactions between 
different opioid receptor subtypes (31,33). 
N20-Induced Antinociception in Mice 
To investigate whether K-opioid receptors might be 
involved, mice were pretreated with 5.0 mg/kg MR-
2266, i.p. (58). MR-2266 [( - )-5,9-diethyl-a-5,9-dialkyl-
2-hydroxy-6,7-benzomorphan] is a K-opioid receptor 
blocker with significant µ,-opioid antagonist properties. 
MR-2266 significantly antagonized N2O-induced anti-
nociception, suggesting that µ,- and/ or K-opioid recep-
tors might be involved in N2O-induced antinociception. 
Further evidence suggesting a role for K-opioid receptors 
in N2O-induced antinociception was demonstrated by 
the marked antagonism of the N2O effect by the K-
selective opioid antagonist norbinaltorphimine (nor-
BNI) (55) . Effective antagonist doses were 50 nmol (36. 7 
µ,g), i.c.v. , and 5.0 nmol (3 .7 µ,g), i.t. Hence, evidence is 
strong that spinal and perhaps supraspinal K-opioid re-
ceptors mediate N2O-induced antinociception in the 
mouse abdominal constriction test. Pretreatment with 
5.0 µ,g of the µ,-selective opioid antagonist {3-funaltrexa-
mine, administered either i.e. v. or i. t., failed to influence 
N2O-induced antinociception, suggesting that µ,-opioid 
receptors are not involved in N2O-induced antinocicep-
tion in the abdominal constriction paradigm. This is also 
supported by the robust antinociceptive effect of N 20 in 
µ,-opioid receptor-deficient CXBK mice (61). The o-
opioid antagonists ICI-174,864 (N,N-diallyl-Tyr-Aib-
Aib-Phe-Leu-OH, where Aib is a -aminoisobutyric acid) 
and naltrindole were ineffective in reducing N20-
induced antinociception in the mouse abdominal con-
striction test (Quock, unpublished findings). 
Additional support for the K-opioid hypothesis of 
N2O-induced antinociception comes from receptor pro-
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tection studies involving pretreatment with ,6-chlornal-
trexamine (,6-CNA), a nonselective alkylator of opioid 
receptor subtypes (79). Mice were pretreated with 2.0 µ,g 
,6-CNA, i.c.v. , then tested for antinociceptive respon-
siveness to 500Jo N2O 24 h later; the antinociceptive effect 
ofN2O was significantly reduced (60). But when K-opioid 
receptors were spared from ,6-CNA alkylation by i.c.v. 
coadministration of 30 µ,g of the K-opioid agonist U-
50,488H {trans(± )-3,4-dichloro-N-methyl-N-[2-(l -pyr-
rolidinyl)cyclohexyl]benzene-acetamide methane sulfo-
nate} , the antinociceptive response to N2O was undimin-
ished. On the other hand, when µ, -opioid receptors were 
protected from ,6-CNA by coadministration of 0.1 µ,g 
of the µ,-opioid ligand CTOP (o-Phe-Cys-Tyr-o-Trp-
Orn-Thr-Pen-Thr-NH2), N2O-induced antinociception 
remained antagonized. Thus, brain K-opioid, but not µ,-
opioid, receptors appear to play a more critical role in 
the antinociceptive effect of N2O in the mouse abdomi-
nal constriction test. 
Experimental evidence suggests the involvement of an 
additional opioid mechanism in the action of N20. Al-
though higher doses of naloxone administered s.c., 
i.c.v., or i.t. produce a dose-related antagonism of N20 -
induced antinociception in the mouse abdominal con-
striction test, ultralow doses exert quite the opposite in-
fluence. Naloxone in pg/kg doses administered s.c. or fg 
doses administered i. t. causes a significant potentiation 
of N2O-induced antinociception (56). Pretreatment i.c.v . 
with fg doses of naloxone had neither an antagonistic 
nor potentiatory influence on N2O-induced antinocicep-
tion. Consistent with the hypothesized K-opioid nature 
of N2O-induced antinociception, ultralow doses of nal-
oxone administered s.c. or i.t., but not i.c.v., had the 
same potentiating outcome on the antinociceptive effect 
of U-50,488H. These results support the concept of a de-
scending opioid system that can inhibit antinociception 
(17-19). Spinal opioid receptors in this system are ul-
trasensitive to antagonism by naloxone at doses so 
extremely low that antinociception induced by adminis-
tration of classical µ,- and K-opioid agonists is not antag-
onized. Hence, ultralow doses of naloxone inactivate 
this antinociception-inhibitory system and potentiate 
the antinociceptive effects of both N2O and U-50,488H. 
N2O-Induced Antinociception in Rats 
Subtype-selective opioid antagonists have also been 
used to study N2O-induced antinociception in the rat hot 
plate paradigm. CTOP is a somatostatin analogue that 
can preferentially block µ, -opioid receptors (37) and se-
lectively antagonize the effects of morphine and the µ,-
selective opioid agonist DAMGO ([o-Ala2MePhe4,Gly-
ol5]enkephalin) in rats (14). Administration i.e. v. of 1 µ,g 
CTOP significantly attenuated the antinociceptive effect 
of 700Jo N2O; increasing the dose to 5 µ,g CTOP failed 
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to increase the degree of antagonism. When CTOP was 
microinjected directly into the periaqueductal gray 
(PAG), a known site of action of morphine antinocicep-
tion (30,80), N2O-induced antinociception was antago-
nized in dose-dependent manner up to an intracerebral 
dose of 1.0 µ,g (32). This localization of µ, -opioid recep-
tors involved in N2O-induced antinociception to the 
P AG is consistent with findings that kainic acid lesions 
of the P AG significantly reduce N2O-induced antinoci-
ception in the tail flick test (81). 
N2O-induced antinociception may also be mediated by 
the 1:-opioid receptor. ,6-Endorphin(l-27) [,6-EP(l - 27)] 
is a molecule of ,6-EP that is truncated by four amino 
acids at the C-terminal. This peptide selectively antago-
nizes the effects of ,6-EP and is a putative 1:-opioid recep-
tor blocker (70). At i.c.v. doses below 5.0 µ,g, ,6-EP(l-
27) produced dose-related antagonism of N2O-induced 
antinociception in the rat hot plate test. At i.e. v. doses 
greater than 5.0 µ,g, the antagonistic activity of ,6-EP(l-
27) was gradually reduced and ,6-EP(l-27) produced a 
dose-related increase in the antinociceptive response to 
700Jo N2O. Rats pretreated with 7.0 µ,g ,6-EP(l - 27) i.c.v. 
demonstrated the greatest variability of responsiveness 
to 700Jo N2O, suggesting that 7.0 µ,g is near the threshold 
dose separating antagonistic and potentiatory influences 
upon N2O-induced antinociception (32). These data are 
consistent with earlier findings that ,6-EP(l-27) has par-
tial agonist activity and can cause antinociception at 
higher doses (25,70). Although ,6-EP(l-27) administered 
i.e. v. reduced N2O-induced antinociception, comparable 
doses administered directly into the P AG had no effect 
on N2O-induced antinociception. ,6-EP(l-27) was not ef-
fective in reducing N2O antinociception when adminis-
tered directly into the PAG. Though the 1:-opioid recep-
tors involved in N2O-induced antinociception do not 
seem to reside in the P AG, possible sites might include 
the raphe obscurus nucleus and raphe pallidus nucleus 
in the caudal medulla oblongata or the medial posterior 
nucleus accumbens, medial preoptic area, and arcuate 
hypothalamic nucleus in the forebrain , which are active 
sites where administration of ,6-EP inhibits the tail flick 
response in rats (76, 77). 
In contrast to the µ,-opioid and 1:-opioid receptors that 
appear to mediate N2O antinociception in the hot plate 
test, other opioid receptor subtypes seem to be involved 
in other tests . When 55- 58 °C water was used as the nox-
ious thermal stimulus, N2O-induced antinociception was 
significantly antagonized by i.c.v. pretreatment with 5.0 
µ,g of the Kl µ,-opioid receptor blocker MR-2266, partly 
reduced by 5.0 µ,g of the a-opioid receptor blocker ICI-
174,864, and unaltered by 10-50 µ,g of the µ,-selective 
opioid antagonist ,6-funaltrexamine (63). These results 
suggest possible involvement of K- and a-opioid, but not 
µ, -opioid, receptors in N2O-induced antinociception in 
the tail withdrawal paradigm. 
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The Pharmacogenetics of 
N20-Induced Antinociception 
Because of the genetic homogeneity within individual 
mouse strains, pharmacological differences between 
strains are indicative of allelic variability between inde-
pendent inbred strains. Comparative studies have in fact 
demonstrated strain-dependent differences in respon-
siveness to N2O-induced antinociception (61). N 20-
induced antinociception was assessed in eight inbred 
strains, and results show the following order of respon-
siveness: A/ J (the most sensitive) ~ C57BL/6ByJ = 
C57BL/6J = BALB/cByJ = C3H/HeJ > CXBK/ByJ 
= CBA/ J > > DBA/2J (the least sensitive) . The weak 
antinociceptive response to N2O in DBA/2J mice, which 
are sensitive to morphine- and U-50,488H-induced anti-
nociception, indicates some underlying neurobiological 
difference in the DBA/2J . 
Subsequent pharmacogenetic studies on N2O-induced 
antinociception have focused on C57BL/6J and DBA/ 
2J strains. These strains are particularly useful for the 
study of the genetic determinants of N2O responsiveness 
for several reasons. First, they have large differences in 
responsiveness to N2O with the C57BL/ 6J strain being 
much more sensitive to N2O-induced antinociception 
than the DBA/2J strain. Second, these strains have 
been compared extensively for differences in morphine-
induced antinociception (the DBA/2J is more sensitive), 
morphine-induced locomotor activation (the C57BL/ 6J 
is more sensitive), and susceptibility to development of 
morphine tolerance and physical dependence (8,24). 
Third, crosses of the C57BL/6J and DBA/2J strains 
have resulted in 26 B x D recombinant inbred (RI) stains. 
Each RI strain is a random recombination of the pro-
genitor chromosomes in a homozygous state as a re-
sult of redistribution of the original F2 genetic variance 
so that it exists almost entirely between strains and is al-
most completely absent within strains. Finally, a large 
number of marker gene loci have now been mapped 
(> 1200). 
Preliminary studies conducted in 22 Bx D RI strains 
revealed a hierarchy of responsiveness to 70% N2O rang-
ing from a < 10% antinociceptive response in the 
B x D-27 / Ty to a 100% response in the Bx D-14 and 
-25 / Ty lines. Cluster analysis showed one cluster of 16 
strains approximating the C57BL/ 6 progenitor (61.9-
100% antinociceptive response to 70% N2O) and an-
other of six strains approximating the DBA/2 progenitor 
(9.1- 40% antinociceptive response to 70% N2O) (62) . 
The robust strain differences permitted screening the 
strain antinociceptive means with marker gene loci pre-
viously mapped in Bx D RI strains . Significant associa-
tions at the 0.002 level were found on seven chromo-
somes, suggesting the presence of quantitative trait loci 
(QTL). As the number of test subjects in each RI strain is 
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increased, the number of promising QTL will be further 
restricted and confirmed. 
The Role of NO in N20-lnduced Antinociception 
A related but far more reactive oxide of nitrogen is 
NO, which consists of a single nitrogen atom coupled to 
a single oxygen atom. In recent years, NO has been rec-
ognized as being an important biological regulator in 
macrophage cytotoxic activity, physiological and phar-
macological vasodilation, and inhibition of platelet ag-
gregation (34,44). Current neurobiological research has 
also identified NO as an intracellular messenger and even 
a new type of neurotransmitter in both the peripheral 
and central nervous systems (7 ,20). Central to investiga-
tions of NO function are drugs that inhibit the key en-
zyme NO synthase (NOS); these include the substituted 
arginines L-N°-nitro arginine (L-NOARG), L-N°-nitro 
arginine methyl ester (L-NAME), L-N°-monomethyl ni-
tro arginine (L-NMMA), and 7-nitro indazole. 
There is recent evidence of a modulatory role played 
by NO in N2O-induced antinociception. In the mouse ab-
dominal constriction paradigm, s.c. pretreatment with 
3.0- 10 mg/ kg L-NOARG caused a dose-related antago-
nism of N2O-induced antinociception (41). Pretreatment 
with 10 mg/kg L-NAME or 10 mg/kg L-NMMA, s.c. , 
also significantly attenuated the antinociceptive effect of 
N2O. Pretreatment with 0.5 µg L-NAME, i.c.v. , also an-
tagonized N2O-induced antinociception. These doses of 
L-NOARG, L-NAME, and L-NMMA alone failed to 
produce any antinociceptive effect. Antagonism of N2O-
induced antinociception by s.c.-administered L-NOARG 
and i.c.v.-administered L-NAME were both reversed by 
i.c.v. treatment with 20 µg L-arginine but not 20 µ,g o-
arginine. Because only the L form of arginine is a sub-
strate for NOS, these results implicate NO in the antino-
ciceptive effect of N20. 
Similar results were obtained in experiments con-
ducted in the rat hot plate test (41) . Pretreatment with 
10- 100 µg L-NOARG, i.c.v., produced a dose-related 
antagonism of N2O-induced antinociception. The antag-
onism of the N2O effect by either 50 µg L-NOARG, 
i.c.v ., or 50 µg L-NAME, i.c.v., was stereospecifically 
reversed by i.c .v. treatment with 10 µ,g L-arginine but not 
10 µ,go -arginine. 
Pretreatment with 10 mg/kg L-NOARG, s.c., failed to 
influence the antinociceptive effects of two other opioid 
drugs, the predominantly µ-opioid agonist morphine 
and the K-selective opioid agonist U-50,488H (41) . The 
failure of NOS inhibition to reduce the antinociceptive 
effects of these direct-acting opioid receptor agonists 
mitigates against the idea that NO is a general mediator 
in central pathways that mediate opioid antinociception. 
Furthermore, in the absence of NOS inhibition, i.e. v. 
treatment with 20 µg L-arginine significantly potentiated 
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N2O-induced antinociception in the mouse abdominal 
constriction test. Yet under similar circumstances, i.e. v. 
treatment with IO µg L-arginine (which reversed L-
NOARG and L-NAME antagonism of N2O) failed to in-
fluence the antinociceptive effect of exposure to 70% 
N2O in the rat hot plate test. Pretreatment with o-
arginine was without effect in either paradigm. The fact 
that increasing brain levels of NO with L-arginine en-
hanced N2O-induced antinociception in mice but not in 
rats might suggest that the contribution of NO to N2O 
action in the two species is not identical. 
What then is the role of NO in N2O-induced antinoci-
ception? One possible explanation is that NO might play 
a role in the mechanism of neuronal release of opioid 
peptides . Tseng and his associates have shown that {3-
EP-induced antinociception is related to stimulated re-
lease of ME in the spinal cord and activation of spinal 
o-opioid receptors by ME (74,75). In urethane-anes-
thetized, i.t. -perfused rats, i.c.v. {3-EP-induced increase 
of ME levels in the i.t. perfusate was significantly sup-
pressed by perfusing with artificial CSF containing 100 
µM L-NOARG (27 ,28,39). The addition of 50 mM 
L-arginine, but not o -arginine, into the CSF perfusate 
reversed the suppression of the ME increase by L-
NOARG. On the other hand, increasing the perfusate 
concentration of L-NOARG to 250 µM failed to produce 
a greater suppression of the {3-EP-induced increase in 
ME. These findings suggest that NO may mediate the {3-
EP-induced release of ME in the spinal cord. If {3-EP is 
the key opioid mediator in N2O in rats, as suggested by 
in vitro release (82) and antibody antagonism studies 
(26), such a role for NO might explain the antagonism 
of N2O antinociception in rats by NOS inhibitors . 
Other research has uncovered an apparent role for NO 
in hyperalgesia at the level of the spinal cord. Synaptic 
plasticity may be intimately involved in the mechanism 
of chronic pain; in a manner analogous to the role it 
plays in long-term potentiation, NO may act as a retro-
grade messenger to maintain a high level of presynaptic 
activity in hyperalgesia (42). A proactive role of NO in 
hyperalgesia is supported by observations of an antinoci-
ceptive effect of NOS inhibitors in mouse tail flick, hot 
plate, abdominal constriction, and formalin-induced 
paw lick tests (46,47). However, the standard challenge 
doses of L-NAME were generally 50-100 mg/kg, which 
was 5- 10 times greater than the IO mg/kg dose used in 
our studies, and the resulting antinociceptive effects 
were not sensitive to antagonism by naloxone. 
Summary 
Twenty years ago, N2O was merely one of a number 
of inhalation anesthetics that was distinguished by an 
unfavorable minimum alveolar concentration and the 
necessity of combining it with a more potent anesthetic 
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agent to produce surgical anesthesia. Recent research, 
however, has revealed additional central pharmacologi-
cal actions (analgesia, anxiolysis) that broaden the clini-
cal applications of N2O. There is increasing evidence of 
an opioid basis to the analgesic effect of N2O. Yet N2O 
appears to be strikingly unlike any other pharmacologi-
cal agent with opioid analgesic properties. The mecha-
nism by which N2O interacts with endogenous opioid 
systems remains uncertain. Various in vitro and in vivo 
investigations have demonstrated N2O-induced release 
of ME and {3-EP, suggesting an indirect mode of action 
of N2O with endogenous opioid systems. Pharmacologi-
cal antagonism of N2O-induced antinociception in ani-
mals has been achieved using first naloxone and then 
various selective receptor blockers to identify the opioid 
receptor subtypes involved in mediating the antinocicep-
tive effect of N2O in mice and rats. The antinociceptive 
effect of N2O in the mouse abdominal constriction test 
appears to be mediated by K-opioid receptors. In con-
trast, N2O-induced antinociception in the rat hot plate 
test apparently involves supraspinal µ- and 1:-opioid re-
ceptors. Future research in inbred mouse strains prom-
ises to help elucidate the neurobiological prerequisites 
for N2O action by uncovering what is aberrant in DBA/ 
2J and Bx D RI strains characterized by poor antinoci-
ceptive responsiveness to Np. Exciting new findings of 
antagonism of N2O-induced antinociception by inhibi-
tion of brain NO production suggests a possible role for 
NO in the mechanism of N2O action, possibly as a regu-
lator of the neuronal release of opioid peptide. It has be-
come increasing apparent that N2O is not only a clini-
cally useful anesthetic and analgesic agent but also a 
unique investigative tool for studying opioid mecha-
nisms. Elucidation of its uncommon mechanism of in-
teraction with opioid systems will produce a better un-
derstanding of the opioid systems themselves . 
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